- Raised $60k grant led by Israel Innovation Authority , Sep 2025
- Raised $8k grant led by Israel Innovation Authority , May 2023
About
Haim Pharma Group (HPG) is an Israel-based virtual drug development company, advancing stabilized synthetic psilocin as a first-in-class therapy for neurodegenerative diseases. The company’s lead focus is amyotrophic lateral sclerosis (ALS), with a parallel program in Parkinson’s disease (PD).
HPG is pioneering an oral enteric-coated psilocin capsule Neurosilin designed for stability and controlled release. A U.S. provisional patent filed in 2025 protects the novel approach to treating neurodegenerative diseases.
The therapeutic concept is based on chronic, sub-hallucinogenic dosing, leveraging psilocin’s multimodal mechanisms: serotonin receptor engagement, restoration of glutamatergic balance, neuroplasticity enhancement, mitochondrial protection, and attenuation of neuroinflammation. Together, these actions aim to slow disease progression and stabilize neuronal viability in ALS and PD.
HPG has taken a proactive regulatory path, engaging with the FDA and submitting a briefing package in July 2025, outlining its development strategy and clinical roadmap.
The company operates through a virtual model, coordinating with global CROs, CDMOs, and academic partners. Its work is guided by experienced clinical and development advisors with deep expertise in neurology, biostatistics, and regulatory strategy.
Haim Pharma group is supported by key knowledge leaders in the area of ALS and clinical trials and is committed to redefining the treatment paradigm for ALS leverage psilocin as a personalized, disease-modifying therapy.
Funding history · 2 rounds · $68K total
Q&A
- What is Haim Pharma Group's primary focus in drug development?
- Haim Pharma Group (HPG) is focused on advancing stabilized synthetic psilocin as a first-in-class therapy for neurodegenerative diseases, with a lead focus on amyotrophic lateral sclerosis (ALS) and a parallel program in Parkinson’s disease (PD).
- What is the name of Haim Pharma Group's pioneering oral psilocin capsule?
- Haim Pharma Group is pioneering an oral enteric-coated psilocin capsule named Neurosilin, designed for stability and controlled release.
- When did Haim Pharma Group file a U.S. provisional patent for its novel approach?
- A U.S. provisional patent protecting Haim Pharma Group's novel approach to treating neurodegenerative diseases was filed in 2025.
- What is Haim Pharma Group's regulatory strategy regarding the FDA?
- Haim Pharma Group engaged with the FDA and submitted a briefing package in July 2025, outlining its development strategy and clinical roadmap.
- How many employees does Haim Pharma Group currently have?
- Haim Pharma Group has 1-10 employees.
- Who is the founder of Haim Pharma Group?
- Miriam O’reilly is the CEO and founder of Haim Pharma Group.
- What was Haim Pharma Group's most recent funding round?
- Haim Pharma Group received a Grant in September 2025, with the Israel Innovation Authority as the lead investor.
- What is the total amount of funding Haim Pharma Group has raised to date?
- Haim Pharma Group has raised a total of $68,000 USD.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | haimpharmagroup.com |
|---|---|
| linkedin.com/company/haim-pharma |
Identifiers & details
| Founded | 2022-4 |
|---|---|
| Employees (exact) | 1 |
Radar intelligence
Patents
| EPO | 10 |
|---|
Web history (Wayback)
| Domain | haimpharmagroup.com |
|---|